ERBB2 and neoplasm: In contrast, the percentage of tumor cells positive for methylated PRKD1 promoter significantly increased in samples from patients with ER+/HER2- IDC (average of 26.9%) and even more in HER2+ (average of 55.4%) or triple-negative (average of 59.7%) samples.